Obtenga las últimas noticias sobre las acciones de Replimune Group con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de REPL

Últimas noticias sobre

REPLIMUNE GROUP INC

Replimune Group

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Replimune Group Inc

REPLENISH NUTRIENTS HLDG by REPLENISH NUTRIENTS HLDG CORP.

Replenish Nutrients Holding Corp

Repligen Corp

Reply SpA

News

Legal

Press Releases

ROSEN, THE FIRST FILING FIRM, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPL

Replimune (REPL) Faces Investor Lawsuit Following 77% Stock Crash After FDA Rejects Key Drug - Hagens Berman

Investors who lost money on Replimune Group, Inc.(REPL) should contact Levi & Korsinsky about pending Class Action - REPL

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL

Replimune Group, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights - REPL

Kirby McInerney LLP Reminds Replimune Group, Inc. Investors of Class Action Filing and Encourages Investors to Contact the Firm

September 22, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against REPL

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm

Replimune Group, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - REPL

REPL

Absci

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics

Astria Therapeutics

Aura Biosciences

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

Emergent BioSolutions

Erasca

I-MAB

Inhibrx Biosciences

ITeos Therapeutics

Kamada

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Nanobiotix

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Prothena Corporation plc - Ordinary Shares

Prothena Corp

PureTech Health plc - American Depositary Shares

Comments

Replimune Group Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL